Ligand id: 8691

Name: begelomab

Immunopharmacology Comments
Begelomab is a DPP4 (CD26)-targeting monoclonal antibody that was in Phase 3 clinical trial vs. conventional second-line treatment for steroid-resistant GvHD (see NCT02411084). The study appears to have been terminated on grounds of insufficient rate of participant recriutment. Mechanistically the antibody targets activated CD26+ T cells that appear to accumulate in the organs of patients with GvHD.
Immunopharmacology Disease
Disease X-Refs Comment References
Graft versus host disease Ex Phase 3 clinical candidate for steroid-resistant GvHD- see NCT02411084.